The quarter marked a dramatic reversal from Q3 FY26's loss-making position, with net profit jumping 213.48% quarter-on-quarter from ₹8.68 crores in Q3 FY26. This performance underscores the company's ability to navigate seasonal volatility whilst maintaining operational leverage, a critical factor for investors assessing the quality of this earnings surprise.
Financial Performance: Margin Expansion Drives Profitability Surge
Borosil Scientific's Q4 FY26 revenue of ₹143.17 crores represented the highest quarterly sales figure in at least seven quarters, marking an 18.03% sequential improvement from ₹121.30 crores in Q3 FY26 and a 10.57% year-on-year gain from ₹129.48 crores in Q4 FY25. The revenue trajectory demonstrates consistent momentum, with the company posting positive quarter-on-quarter growth across the past four consecutive quarters after a temporary setback in Q2 FY26.
| Quarter | Revenue (₹ Cr) | QoQ Growth | Net Profit (₹ Cr) | QoQ Growth | Operating Margin | PAT Margin |
|---|---|---|---|---|---|---|
| Mar'26 | 143.17 | +18.03% | 27.21 | +213.48% | 22.43% | 19.03% |
| Dec'25 | 121.30 | +13.47% | 8.68 | +200.35% | 14.17% | 7.17% |
| Sep'25 | 106.90 | +11.38% | 2.89 | -169.47% | 7.50% | 2.67% |
| Jun'25 | 95.98 | -25.87% | -4.16 | -147.98% | 5.08% | -4.39% |
| Mar'25 | 129.48 | +27.63% | 8.67 | +101.63% | 12.79% | 6.66% |
| Dec'24 | 101.45 | -1.49% | 4.30 | -51.08% | 9.87% | 4.22% |
| Sep'24 | 102.98 | — | 8.79 | — | 15.36% | 8.55% |
The standout feature of Q4 FY26 was the dramatic margin expansion. Operating profit (PBDIT excluding other income) surged to ₹32.11 crores, yielding an operating margin of 22.43%—the highest in at least seven quarters and a substantial improvement from 12.79% in Q4 FY25. This 963 basis point year-on-year margin expansion reflects improved operating leverage and cost discipline. Quarter-on-quarter, operating margin expanded by 826 basis points from 14.17% in Q3 FY26, demonstrating the company's ability to scale profitability as revenue grows.
PAT margin of 19.03% in Q4 FY26 represented a remarkable 1,237 basis point improvement from 6.66% in Q4 FY25, driven not only by operational efficiency but also by an unusually low effective tax rate of 6.52% compared to 38.59% in the prior-year quarter. This tax benefit contributed significantly to the bottom-line surge, raising questions about normalised profitability levels going forward.
Operational Excellence: Cost Control Amplifies Revenue Growth
Borosil Scientific's operational turnaround in Q4 FY26 was underpinned by disciplined cost management across multiple expense categories. Employee costs declined to ₹17.94 crores from ₹21.57 crores in Q3 FY26, despite the 18% sequential revenue increase—a testament to improved productivity and workforce optimisation. This reduction in employee expenses as a percentage of revenue from 17.78% to 12.53% directly contributed to margin expansion.
Interest expenses remained negligible at ₹0.26 crores, consistent with the company's minimal debt profile. Depreciation of ₹4.76 crores remained stable, reflecting a steady asset base. The combination of revenue growth and controlled fixed costs created powerful operating leverage, with profit before tax (PBT) surging to ₹29.15 crores from ₹12.65 crores in Q3 FY26 and ₹14.02 crores in Q4 FY25.
Tax Rate Anomaly: A One-Time Benefit?
The effective tax rate of 6.52% in Q4 FY26 stands in stark contrast to the 31.23% rate in Q3 FY26 and 38.59% in Q4 FY25. This unusually low tax incidence boosted reported net profit by approximately ₹7-8 crores compared to normalised taxation levels. Investors should note that if the company had been taxed at its historical average rate of around 32-38%, normalised PAT would have been closer to ₹19-20 crores rather than ₹27.21 crores. Whilst still representing strong performance, this adjustment provides a more realistic baseline for future quarters.
From a capital efficiency perspective, the company's return on equity (ROE) of 4.53% remains concerningly weak, ranking amongst the lowest in its peer group. Return on capital employed (ROCE) of 6.91% similarly lags industry standards, suggesting that whilst quarterly profitability has improved, the company has yet to demonstrate sustained high-quality returns on invested capital. For a manufacturing business, these metrics indicate significant room for improvement in asset utilisation and capital allocation.
Balance Sheet Quality: Fortress Balance Sheet Provides Strategic Flexibility
Borosil Scientific's balance sheet as of March 2025 reflects conservative financial management with minimal leverage. Total shareholder funds stood at ₹404.39 crores, comprising equity capital of ₹8.89 crores and reserves of ₹395.49 crores. Long-term debt of just ₹1.74 crores represents a negligible 0.43% of total equity, positioning the company as virtually debt-free.
The company's net debt-to-equity ratio of -0.27 indicates a net cash position, with cash and liquid investments exceeding total borrowings. This financial cushion provides management with strategic flexibility to pursue growth investments, acquisitions, or return cash to shareholders without financial constraint. Current assets of ₹309.95 crores comfortably exceed current liabilities of ₹87.13 crores, yielding a healthy current ratio of 3.56x—well above the 1.5x threshold considered prudent for manufacturing businesses.
Fixed assets of ₹187.47 crores represent the company's manufacturing infrastructure, with the modest decline from ₹192.24 crores in FY24 reflecting normal depreciation patterns. The absence of aggressive capital expenditure suggests management is focused on sweating existing assets rather than pursuing capacity expansion, which aligns with the company's focus on improving returns on existing capital before deploying fresh investments.
Cash Flow Strength: Operations Generate Robust Cash
For FY25, Borosil Scientific generated operating cash flow of ₹120 crores, a dramatic improvement from ₹30 crores in FY24. This fourfold increase was driven by strong working capital management, with changes in working capital contributing ₹72 crores positively. The company deployed ₹115 crores in investing activities, likely towards capital expenditure and strategic investments, whilst financing cash flow of -₹3 crores reflected debt repayment. The net cash position improved to ₹13 crores from ₹12 crores, demonstrating the company's ability to fund growth organically whilst maintaining financial flexibility.
Industry Context: Industrial Products Sector Faces Headwinds
Borosil Scientific operates within the industrial products sector, which has experienced mixed performance over the past year. The broader Industrial Products sector delivered an average return of 8.73% over the past twelve months, whilst Borosil Scientific's stock returned just 3.28%, underperforming its sector by 5.45 percentage points. This underperformance reflects investor concerns about the company's inconsistent quarterly results and weak return ratios, despite the recent Q4 FY26 surge.
The laboratory glassware and scientific equipment market in India remains fragmented, with demand driven by research institutions, educational laboratories, pharmaceutical companies, and quality control facilities. Borosil Scientific's established brand presence and manufacturing capabilities provide competitive advantages, but the company faces pricing pressure from imports and competition from unorganised players. The sector's growth trajectory is tied to India's research and development spending, pharmaceutical industry expansion, and educational infrastructure development—all of which provide long-term tailwinds but can be volatile quarter-to-quarter.
Peer Comparison: Valuation Premium Despite Weaker Returns
Borosil Scientific's valuation metrics reveal a significant premium to historical norms despite lagging operational performance relative to peers. At a price-to-earnings (P/E) ratio of 52.81x based on trailing twelve-month earnings, the stock trades at a substantial premium to the industrial products sector average P/E of 37x. This 43% valuation premium appears difficult to justify given the company's weak return profile.
| Company | Market Cap (₹ Cr) | P/E (TTM) | P/BV | ROE (%) | Debt/Equity |
|---|---|---|---|---|---|
| Borosil Scientific | 1,073 | 52.81 | 3.13 | 4.53 | -0.27 |
| Pix Transmission | — | 19.10 | 3.27 | 18.22 | -0.36 |
| Belding India | — | NA (Loss Making) | 312.18 | 6.92 | -0.11 |
| Vidya Wires | — | 32.67 | 3.90 | 0.00 | 0.00 |
| Wendt India | — | 96.22 | 5.51 | 15.84 | -0.30 |
| Tinna Rubber | — | 27.31 | 4.92 | 22.59 | 0.35 |
Borosil Scientific's ROE of 4.53% ranks at the bottom of its peer group, with Tinna Rubber generating 22.59% ROE and Pix Transmission delivering 18.22%. This stark differential in capital efficiency raises questions about whether the company's valuation premium of 52.81x P/E is sustainable. The price-to-book value (P/BV) ratio of 3.13x appears reasonable relative to peers, excluding the outlier Belding India, but remains elevated given the company's sub-par return generation.
The company's net cash position (debt-to-equity of -0.27) provides a competitive advantage in terms of financial flexibility, matching the conservative balance sheet profiles of peers like Pix Transmission and Wendt India. However, this financial strength has not translated into superior returns on equity, suggesting operational rather than financial constraints are limiting value creation.
Valuation Analysis: Expensive Multiples Price In Perfection
Borosil Scientific's current valuation of ₹141.80 per share implies a market capitalisation of ₹1,073 crores and an enterprise value of approximately ₹1,050 crores after adjusting for net cash. At 52.81x trailing earnings, the stock trades at a significant premium to both its sector (37x P/E) and its own historical averages. The company's valuation grade has fluctuated between "Expensive" and "Very Expensive" over the past year, currently sitting at "Expensive" after a brief downgrade in July 2025.
The enterprise value-to-EBITDA multiple of 24.87x appears elevated for a company generating ₹60 crores of annual EBITDA with inconsistent quarterly performance. The EV/EBIT ratio of 42.24x further underscores the premium valuation, suggesting investors are pricing in substantial future growth and margin expansion that has yet to materialise consistently.
The stock's 52-week range of ₹96.65 to ₹190.45 illustrates significant volatility, with the current price of ₹141.80 sitting 25.54% below the peak and 46.71% above the trough. This volatility reflects uncertainty about the sustainability of quarterly earnings and the company's ability to maintain the margin levels achieved in Q4 FY26. The absence of dividend payments (zero payout ratio) means investors are entirely dependent on capital appreciation, increasing the importance of consistent earnings growth to justify current valuations.
Based on normalised earnings (adjusting for the unusually low tax rate) and assuming sustainable PAT margins of 12-14% rather than the Q4 FY26 level of 19%, a fair value estimate would place the stock closer to ₹105-120 per share, implying 15-26% downside risk from current levels. This assessment assumes the company can maintain improved operational performance whilst reverting to normalised tax rates.
Shareholding Pattern: Stable Promoter Base, Limited Institutional Interest
Borosil Scientific's shareholding pattern reflects a promoter-dominated structure with minimal institutional participation. Promoter holding increased marginally to 68.08% in Q4 FY26 from 67.81% in the previous quarter, demonstrating continued confidence from the founding family. The Kheruka family, led by Kiran Kheruka (25.52%), Rekha Kheruka (13.86%), and Pradeep Kumar Kheruka (11.16%), along with associated entities, maintains firm control over the company's strategic direction.
| Shareholder Category | Mar'26 | Dec'25 | Sep'25 | QoQ Change |
|---|---|---|---|---|
| Promoter | 68.08% | 67.81% | 67.81% | +0.27% |
| FII | 0.09% | 0.07% | 0.07% | +0.02% |
| Mutual Funds | 0.01% | 0.01% | 0.01% | — |
| Insurance | 0.00% | 0.00% | 0.00% | — |
| Other DII | 0.26% | 0.18% | 0.09% | +0.08% |
| Non-Institutional | 31.56% | 31.93% | 32.02% | -0.37% |
The near-total absence of institutional investors represents a significant concern. Foreign institutional investors (FIIs) hold just 0.09%, mutual funds own a negligible 0.01%, and insurance companies have zero exposure. This lack of institutional interest likely reflects concerns about the company's small size, inconsistent earnings, weak return metrics, and limited liquidity. The total institutional holding of 0.35% is extraordinarily low for a listed company, suggesting sophisticated investors remain unconvinced about the investment case despite recent operational improvements.
Other domestic institutional investors (DIIs) have been incrementally increasing their stake, rising from 0.09% in September 2025 to 0.26% in March 2026. Whilst this represents positive momentum, the absolute level remains minuscule. Non-institutional shareholders, representing retail and high-net-worth individuals, declined marginally to 31.56% from 31.93%, indicating some profit-booking following the strong quarterly results.
Positively, there is zero promoter pledging, eliminating concerns about financial stress or forced selling. The promoter group's willingness to maintain and marginally increase their stake signals alignment with minority shareholders and confidence in the company's long-term prospects.
Stock Performance: Exceptional Short-Term Gains Mask Longer-Term Struggles
Borosil Scientific's stock has delivered exceptional returns over short-term horizons, driven primarily by the Q4 FY26 results and recovery from oversold levels. The one-day surge of 19.36% to ₹141.80 following the earnings announcement reflects investor enthusiasm about the profitability turnaround. Over the past week, the stock has gained 25.60%, dramatically outperforming the Sensex's 0.95% gain and generating positive alpha of 24.65 percentage points.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Day | +19.36% | +0.16% | +19.20% |
| 1 Week | +25.60% | +0.95% | +24.65% |
| 1 Month | +22.19% | -4.08% | +26.27% |
| 3 Months | +26.38% | -9.05% | +35.43% |
| 6 Months | +10.26% | -12.04% | +22.30% |
| YTD | +18.12% | -11.62% | +29.74% |
| 1 Year | +3.28% | -7.23% | +10.51% |
The three-month return of 26.38% and six-month gain of 10.26% demonstrate strong recovery momentum from the 52-week low of ₹96.65 touched earlier in the year. Year-to-date, the stock has gained 18.12%, significantly outperforming the Sensex's 11.62% decline and generating alpha of 29.74 percentage points. This outperformance reflects both company-specific improvements and broader market rotation into micro-cap industrial names.
However, the one-year return of just 3.28% reveals a more sobering picture. Whilst the stock has outperformed the Sensex's 7.23% decline over this period, the absolute return remains modest and lags the Industrial Products sector's 8.73% gain. The underperformance versus peers highlights investor scepticism about earnings sustainability, with the stock having experienced significant volatility between the 52-week high of ₹190.45 and low of ₹96.65—a 97% range.
From a technical perspective, the stock has broken above all key moving averages, trading above the 5-day (₹123.41), 20-day (₹118.70), 50-day (₹112.88), 100-day (₹112.47), and 200-day (₹124.73) moving averages. The technical trend has shifted to "Mildly Bullish" as of May 19, 2026, supported by bullish signals from OBV (On-Balance Volume) and Dow Theory indicators. However, weekly MACD remains only "Mildly Bullish" and RSI shows "No Signal," suggesting the technical setup is not overwhelmingly positive despite recent price strength.
The stock's beta of 1.50 indicates high volatility relative to the broader market, with annualised volatility of 49.35% classifying it as a "High Risk High Return" investment. This volatility profile suits aggressive investors but may prove uncomfortable for conservative portfolios seeking stable returns.
Investment Thesis: Quality Concerns Temper Valuation Appeal
Borosil Scientific's investment case rests on three pillars: operational improvement, balance sheet strength, and technical momentum. The company's Q4 FY26 results validate management's ability to drive margin expansion when revenue growth materialises, whilst the debt-free balance sheet provides strategic flexibility. Technical indicators support near-term positive momentum, with the stock breaking above key resistance levels.
However, significant concerns temper enthusiasm. The company's average quality grade reflects weak return ratios, with ROE of 4.53% and ROCE of 6.91% ranking amongst the poorest in the peer group. Long-term growth has been modest, with five-year sales CAGR of 9.80% and EBIT growth of just 2.86%, indicating limited operating leverage over extended periods. The unusually low tax rate of 6.52% in Q4 FY26 artificially inflated reported profits, raising questions about normalised earning power.
The "Expensive" valuation grade and 52.81x P/E ratio leave little room for disappointment. At current valuations, the market has priced in sustained margin expansion and revenue growth acceleration—outcomes that remain uncertain given the company's inconsistent track record. The near-total absence of institutional investors (0.35% holding) signals that sophisticated market participants remain unconvinced, despite recent operational improvements.
Key Strengths & Risk Factors
KEY STRENGTHS
- Spectacular Q4 FY26 profitability with net profit of ₹27.21 crores, up 213.84% YoY
- Operating margin expansion to 22.43%, highest in seven quarters
- Debt-free balance sheet with net cash position (debt-to-equity: -0.27)
- Strong current ratio of 3.56x provides liquidity cushion
- Zero promoter pledging eliminates governance concerns
- Robust operating cash flow of ₹120 crores in FY25, up 4x YoY
- Technical breakout above all major moving averages
KEY CONCERNS
- Weak ROE of 4.53% and ROCE of 6.91% indicate poor capital efficiency
- Inconsistent quarterly performance with Q2 FY26 loss of ₹4.16 crores
- Unusually low tax rate of 6.52% in Q4 FY26 inflates reported profits
- Premium valuation at 52.81x P/E versus sector average of 37x
- Negligible institutional holding of 0.35% signals lack of sophisticated investor interest
- Modest long-term growth: 9.80% sales CAGR, 2.86% EBIT CAGR over 5 years
- High volatility (49.35% annualised) increases risk profile
Outlook: Monitoring Points for Sustainability
POSITIVE CATALYSTS
- Sustained revenue growth above ₹140 crores quarterly
- Operating margins stabilising at 18-20% range
- Tax rate normalisation to 30-32% with maintained profitability
- Institutional investor participation increasing above 2-3%
- ROE improvement towards 10-12% through better asset utilisation
RED FLAGS
- Revenue declining below ₹120 crores in Q1 FY27
- Operating margins reverting below 12-14%
- Return to quarterly losses or sub-₹5 crore profitability
- Promoter stake reduction or pledging initiation
- Inability to sustain improved working capital management
The Verdict: Impressive Quarter, But Sustainability Questions Persist
Score: 64/100
For Fresh Investors: Not recommended for fresh purchases at current valuations. The 52.81x P/E ratio prices in perfection, whilst the company's track record of inconsistent quarterly performance and weak return ratios (ROE: 4.53%) suggest significant execution risk. The unusually low tax rate of 6.52% in Q4 FY26 artificially inflated profits, with normalised earnings likely 25-30% lower. Wait for sustained margin performance over 2-3 quarters and valuation correction towards ₹105-120 before considering entry.
For Existing Holders: Continue holding with trailing stop-loss. The debt-free balance sheet and operational improvements provide a foundation for long-term value creation, but monitor quarterly results closely for margin sustainability. Consider partial profit-booking if stock approaches ₹160-170 levels (previous resistance zone) or if Q1 FY27 results disappoint. The absence of institutional interest remains a concern that limits upside potential until quality metrics improve.
Fair Value Estimate: ₹110-120 (15-22% downside risk from current levels based on normalised earnings and sustainable margin assumptions)
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance does not guarantee future results. The views expressed are based on data available as of May 20, 2026, and are subject to change based on market conditions and company performance.
